Req .: 4000.0460.

3750 / RGH 189 MO # 240777

Patient: Sr. Eoram Dobner de Lima

Birth Date: 22/02/1995 Male
Requesting Physician: Dr (a) LEANDRO SANTINI ECHENIQUE
Origin: RONDOX HEALTH TRAVEL CENTRE

Collection Date: 01/02/2022, 08:36 BRT Receipt Date: 01/02/2022

Material: Nasopharyngeal Swab
Exam: SARS-CoV-2 (COVID19)

Result: NOT DETECTED.

Reference value: Not detected.

Technique: Research of SARS-CoV-2 (COVID19) through RNA extraction, reverse transcription and amplification of two fragments of the viral
genome using the Real Time Polymerase Chain Reaction (RT-PCR) technique.

Interpretation: The detection of the SARS-CoV-2 virus (the causative agent of COVID19) occurs through the amplification of two specific regions of the viral
genome recommended by the CDC (USA). There are four possible results, they are: (1) DETECTED: samples where the two target regions of the viral genome
are amplified. This is indicative of the presence of the virus in the sample. (2) NOT DETECTED: samples where the two target regions of the viral genome are not
amplified. The reaction control amplifies before cycle 40 of the RT-PCR. This is indicative of the absence of the virus in the sample; (3) INCONCLUSIVE: samples
where only one of the target regions of the viral genome is amplified. Reaction control amplifies before cycle 40 of RT-PCR; (4) INVALID: there is no amplification
of the internal control or the amplification occurred after cycle 40 of the RT-PCR.

Precaution: Factors such as inadequate sample collection, type of biological sample, time elapsed between collection and onset of symptoms and fluctuation
of viral load can influence the test result. If there is a discrepancy between the test result and the patient's clinical condition, it is recommended that the test be
repeated in another sample of the respiratory tract.

Note: This test uses primers and probes developed by the company IDT (USA) that bind to two specific regions of the viral RNA. As an internal control, we
use primers and probes that amplify RNAseP. Validation and proficiency were performed with samples provided by Instituto Adolfo Lutz (SP).

Technical responsible: Dr. Luiz Heraldo A. Camara Lopes - CRM: 15840 4000.0460.3750
Ireland PG 1 of 1
and Quality Control Program Brazilian Society of Pathology
3988343306